(Q43969727)

28 November 2017

title

Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial (English)

1 reference

28 November 2017

1 reference

1 reference

1

1 reference

28 November 2017

Christine Rivierre

2

1 reference

28 November 2017

Hilary A Jackson

3

1 reference

28 November 2017

K Marcy Murphy

4

1 reference

28 November 2017

Gigi Davidson

5

1 reference

28 November 2017

Candace A Sousa

6

1 reference

28 November 2017

publication date

1 April 2002

1 reference

28 November 2017

published in

Veterinary Dermatology

1 reference

28 November 2017

volume

13

1 reference

28 November 2017

issue

2

1 reference

28 November 2017

page(s)

77-87

1 reference

Mechanisms of action of cyclosporine.

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3164.2002.00283.X

FK506 and cyclosporin A inhibit stem cell factor-dependent cell proliferation/survival, while inducing upregulation of c-kit expression in cells of the mast cell line MC/9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3164.2002.00283.X

The effects of cyclosporin A, dexamethasone and other immunomodulatory drugs on induced expression of IL-3, IL-4 and IL-8 mRNA in a human mast cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3164.2002.00283.X

Effect of cyclosporin A on the allergen-induced late asthmatic reaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3164.2002.00283.X

Inhibitory effect of cyclosporin A on antigen and alloantigen presenting capacity of human epidermal Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3164.2002.00283.X

The effects of cyclosporin A on non-T cell components of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3164.2002.00283.X

Cyclosporin in atopic dermatitis: review of the literature and outline of a Belgian consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3164.2002.00283.X

Clinical anti-inflammatory efficacy of arofylline, a new selective phosphodiesterase-4 inhibitor, in dogs with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3164.2002.00283.X

The ACVD task force on canine atopic dermatitis (XXIII): are essential fatty acids effective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3164.2002.00283.X

The ACVD task force on canine atopic dermatitis (XX): glucocorticoid pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3164.2002.00283.X

Cutaneous papillomatous hyperplasia in cyclosporine-A treated beagles

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3164.2002.00283.X

Cyclosporin clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3164.2002.00283.X

The ACVD task force on canine atopic dermatitis: forewords and lexicon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-3164.2002.00283.X

10.1046/J.1365-3164.2002.00283.X

21 January 2018

Identifiers

DOI

1 reference

28 November 2017

1 reference